Group 5A: HER2+ Breast & Pan-Cancers; Clinical Trials; Immunotherapy; Novel Targets & Therapies

Poster #TPS2666: A phase 1, first-in-human (FIH) study of autologous macrophages engineered to express an anti-HER2 chimeric antigen receptor (CAR) in participants (pts) with HER2-overexpressing solid tumors

Poster #532: A multicenter phase II study of vaccines to prevent recurrence in patients with HER-2–positive breast cancer